Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
ASTRAZENECA LIMITED,Acalabrutinib,"Chronic lymphocytic leukaemia (CLL), as subsequent line of therapy to venetoclax regimens for those relapsed or refractory within 36 months or have intolerable side effects with venetoclax",Acalabrutinib (CALQUENCEÂ®),Only if cost neutral or cost saving,Community and Hospital,Oncology Agents and Immunosuppressants
